Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Benefits of Living Over Deceased Donor Kidney Transplantation in Elderly Recipients. A Propensity Score Matched Analysis of a Large European Registry Cohort

  • Toapanta, Néstor|||0000-0001-5983-6863
  • Comas, Jordi|||0000-0001-5257-7029
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Manonelles, Anna|||0000-0003-2456-388X
  • Facundo, Carme|||0000-0003-1254-5553
  • Pérez-Sáez, María José|||0000-0002-8601-2699
  • Vila, Anna
  • Arcos, Emma
  • Tort, Jaume
  • Giral, Magali|||0000-0001-7641-1592
  • Naesens, Maarten|||0000-0002-5625-0792
  • Kuypers, Dirk RJ.|||0000-0001-5546-9680
  • Åsberg, Anders|||0000-0002-0628-1769
  • Moreso, Francesc|||0000-0002-7267-3963
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
Although kidney transplantation from living donors (LD) offers better long-term results than from deceased donors (DD), elderly recipients are less likely to receive LD transplants than younger ones. We analyzed renal transplant outcomes from LD versus DD in elderly recipients with a propensity-matched score. This retrospective, observational study included the first single kidney transplants in recipients aged ≥65 years from two European registry cohorts (2013-2020, n = 4,257). Recipients of LD (n = 408), brain death donors (BDD, n = 3,072), and controlled cardiocirculatory death donors (cDCD, n = 777) were matched for donor and recipient age, sex, dialysis time and recipient diabetes. Major graft and patient outcomes were investigated. Unmatched analyses showed that LD recipients were more likely to be transplanted preemptively and had shorter dialysis times than any DD type. The propensity score matched Cox's regression analysis between LD and BDD (387-pairs) and LD and cDCD (259-pairs) revealing a higher hazard ratio for graft failure with BDD (2.19 [95% CI: 1.16-4.15], p = 0.016) and cDCD (3.38 [95% CI: 1.79-6.39], p < 0.001). One-year eGFR was higher in LD transplants than in BDD and cDCD recipients. In elderly recipients, LD transplantation offers superior graft survival and renal function compared to BDD or cDCD. This strategy should be further promoted to improve transplant outcomes.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

  • León-Román, Juan
  • Bolufer Cardona, Monica
  • Sánchez-Salinas, Mario
  • Alonso-Martínez, Carla
  • Bestard, Oriol
  • Bermejo García, Sheila
  • Cecilia del Carmen, Carpio Segura
  • Garcia-Carro, Clara
  • Barba, Pere
  • Soler, María José
  • IACOBONI, GLORIA
CAR-T therapy; Acute kidney injury; Onconephrology, Terapia CAR-T; Lesión renal aguda; Onconefrología, Teràpia CAR-T; Lesió renal aguda; Onconefrologia, Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients., P.B. received research funding from the Carlos III Health Institute (PI21/0199,INT23/00072), Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Prediabetes and CKD: Does a causal relationship exist, Prediabetes y ERC: ¿existe una relación causal?

  • Rico-Fontalvo, Jorge
  • daza arnedo, rodrigo andres
  • Navarro-Blackaller, Guillermo
  • Medina-Gonzalez, Ramon
  • Rodriguez Yanez, Tomas
  • Soler, María José
Prediabetes; Chronic kidney disease; Albuminuria, Prediabetes; Enfermedad renal crónica; Albuminuria, Prediabetis; Malaltia renal crònica; Albuminuria, The relationship between diabetes and the development of kidney complications is well known, but the understanding of prediabetes and insulin resistance with impaired kidney function has been scarcely assessed. Various factors could explain this phenomenon, from the lack of standardization in the definitions of prediabetes, to the erratic and inconsistent evidence in large-scale epidemiological and cohort studies. It seems that the pathophysiological pathway of prediabetes could be related to inflammation and neurohormonal hyperactivation, factors present even before the onset of diabetes, which might be the main drivers of glomerular hyperfiltration, albuminuria, and impaired glomerular filtration rate. It is possible that existing treatments for the management of diabetes, as metformin or SGLT2 inhibitors may also be useful in patients with prediabetes with evidence of functional and structural kidney damage. The purpose of this review is to summarize the evidence regarding the relationship between prediabetes (preDM) and the development of CKD., La relación entre diabetes y el desarrollo de complicaciones renales es bien conocida; sin embargo la asociación entre prediabetes y la resistencia a la insulina con el daño en la función renal apenas ha sido evaluada. Varios factores podrían explicar este fenómeno, desde la falta de estandarización en las definiciones de prediabetes, hasta la errática e inconsistente evidencia en estudios epidemiológicos y de cohortes a gran escala. Parece que las vías fisiopatológicas en la prediabetes podrían estar relacionadas con inflamación y la hiperactivación del sistema neuro-hormonal, factores presentes incluso antes de la aparición de la diabetes, que podrían ser los principales impulsores de la hiperfiltración glomerular, albuminuria y alteración de la tasa de filtración glomerular. Es posible que los tratamientos existentes para el control de la diabetes, como metformina o los inhibidores SGLT2 también pueden ser útiles en pacientes con prediabetes con evidencia de daño renal funcional o estructural. El propósito de esta revisión es resumir la evidencia sobre la relación entre la prediabetes (preDM) y el desarrollo de la ERC., M.J.S. is funded by ISCIIII-FEDER and ISCIII, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units

  • León-Román, Juan
  • Azancot Rivero, M Antonieta
  • Marouço, Catarina
  • Patricio-Liébana, Marc
  • Ramos Terrades, Natalia
  • Núñez Delgado, Sara
  • Zamora Carrillo, Jorge Ivan
  • TOAPANTA, NÉSTOR
  • Méndez Fernández, Ana Belén
  • Soler, María José
Cardiorenal syndrome; Chronic kidney disease; Heart failure, Síndrome cardiorrenal; Enfermedad renal crónica; Insuficiencia cardíaca, Síndrome cardiorenal; Malaltia renal crònica; Insuficiència cardíaca, Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this study is to evaluate the clinical performance of patients with CRS who are followed up by the Cardiorenal Unit (CRU). Methods: We conducted a retrospective observational study of patients referred to the CRU from April 1, 2022, to April 30, 2023. Demographics, laboratory and ultrasonographic tests, and outcomes were evaluated. Results: Fifty-four patients were seen in the CRU. A total of 45 (83%) and 16 (30%) patients completed follow-up in the CRU at 6 and 12 months, respectively. The mean age was 70 years ± 1.6, and 65% were men. Almost 50% of patients had ischemic heart disease-related HF. The mean cardiac ejection fraction (EF) was 40% ± 1.6, and 61% of patients had HF with reduced EF (HFrEF). NYHA functional classes II and III were the most frequent (60% and 35%, respectively). At 6 months after follow-up, treatment was optimized with sacubitril-valsartan in 33% vs. 49% (p = 0.02) and SGLT2 inhibitors in 48% vs. 72% (p = 0.008), without significant deterioration in renal function (creatinine: p = 0.61; eGFR: p = 0.19). There was also a reduction of more than 50% in the number of hospital admissions (p = 0.002). A total of 22% required peritoneal dialysis, and 20% required hemodialysis. Ten (19%) patients died, five of them due to cardiovascular (CV) events. Conclusions: The CRU is vital for the management of complex patients as it ensures the implementation of medications that reduce CV mortality and decrease the number of hospital admissions in HF., This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, Grant No. PI21/01292, PI24/01510, ERA PerMed JTC2022 Grant No. AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas, PI23/01209 Proyectos de I+D+I en Salud AES2023.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy

  • Martín Agramunt, Maria
  • Llorens Cebrià, Carmen
  • León-Román, Juan
  • Pérez Beltran, Víctor
  • Saumell, Silvia
  • Torres, Irina B.
  • López González, Mercedes
  • Perurena-Prieto, Janire
  • Agraz Pamplona, Irene
  • Sellarès , Joana
  • Ramos Terrades, Natalia
  • Bestard, Oriol
  • Moreso, Francesc
  • Ariceta Iraola, Gema
  • Soler, María José
  • Hernandez-Gonzalez, Manuel
  • Jacobs-Cacha, Conxita
Biomarkers; C5 blockade; Complement system, Biomarcadors; Bloqueig C5; Sistema del complement, Biomarcadores; Bloqueo C5; Sistema del complemento, Introduction Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing aHUS. There is no gold standard test to monitor disease activity; however, the ex vivo C5b-9 deposition test seems to be a good approach. Methods We assessed the C5b-9 deposition induced by serum samples of patients with aHUS (n = 8) and with TMA associated with kidney (n = 2), lung (n = 1) or hematopoietic stem cell (HSC) transplantation (HSCT, n = 2) during the acute phase of the disease or in remission. As control for transplant-associated TMA (TA-TMA), we analyzed samples of clinically stable kidney and HSC-transplanted patients without signs of TMA. In addition, we studied 1 child with genetic risk of aHUS during an acute infection. Results In the acute disease phase or in patients with disease activity despite C5 blockade, a significant increase of C5b-9 deposition was detected. In all patients with clinical response to C5 blockade but one, levels of C5b-9 deposition were within the normal range. Finally, we detected increased C5b-9 deposition levels in an asymptomatic child with genetic risk of aHUS when a concomitant otitis episode was ongoing. Conclusion The ex vivo C5b-9 deposition test is an auspicious tool to monitor CS activity in aHUS and TA-TMA. In addition, we demonstrate that the test may be useful to detect subclinical increase of CS activity, which expands the spectrum of patients that would benefit from a better CS activity assessment., This study was funded with a research grant from Alexion and a grant from the Spanish Society of Nephrology. JL-R is recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM23/00213). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292), Fundació la Marató de TV3 (202017-10, 202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS)

  • Núñez-Seral, Norberto
  • Martínez Díaz, Irene
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Villena-Ortiz, Yolanda
  • Soler, María José
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
Apolipoproteína; Cromatografía líquida; Espectrometría de masas, Apolipoprotein; Liquid chromatography; Mass spectrometry, Apolipoproteïna; Cromatografia líquida; Espectrometria de masses, Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist., C.L.C. performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. We thank Mandy Rettel from the PCF of EMBL for technical assistance. The study was funded with a grant from Fundació la Marató de TV3 (ref 202017-10). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292) and Fundació la Marató de TV3 (202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, drug delivery, and therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy

  • Martín Agramunt, Maria
  • Llorens Cebrià, Carmen
  • León-Román, Juan
  • Pérez Beltran, Víctor
  • Saumell, Silvia
  • Torres, Irina B.
  • López González, Mercedes
  • Perurena-Prieto, Janire
  • Agraz Pamplona, Irene
  • Sellarès , Joana
  • Ramos Terrades, Natalia
  • Bestard, Oriol
  • Moreso, Francesc
  • Ariceta Iraola, Gema
  • Soler, María José
  • Hernandez-Gonzalez, Manuel
  • Jacobs-Cacha, Conxita
Biomarkers; C5 blockade; Complement system, Biomarcadors; Bloqueig C5; Sistema del complement, Biomarcadores; Bloqueo C5; Sistema del complemento, Introduction Atypical hemolytic uremic syndrome (aHUS) is a complement system (CS)–mediated ultrarare disease that manifests as thrombotic microangiopathy (TMA) with preferential small kidney vessels involvement. Transient CS activation is also observed in secondary TMA or in patients at risk of developing aHUS. There is no gold standard test to monitor disease activity; however, the ex vivo C5b-9 deposition test seems to be a good approach. Methods We assessed the C5b-9 deposition induced by serum samples of patients with aHUS (n = 8) and with TMA associated with kidney (n = 2), lung (n = 1) or hematopoietic stem cell (HSC) transplantation (HSCT, n = 2) during the acute phase of the disease or in remission. As control for transplant-associated TMA (TA-TMA), we analyzed samples of clinically stable kidney and HSC-transplanted patients without signs of TMA. In addition, we studied 1 child with genetic risk of aHUS during an acute infection. Results In the acute disease phase or in patients with disease activity despite C5 blockade, a significant increase of C5b-9 deposition was detected. In all patients with clinical response to C5 blockade but one, levels of C5b-9 deposition were within the normal range. Finally, we detected increased C5b-9 deposition levels in an asymptomatic child with genetic risk of aHUS when a concomitant otitis episode was ongoing. Conclusion The ex vivo C5b-9 deposition test is an auspicious tool to monitor CS activity in aHUS and TA-TMA. In addition, we demonstrate that the test may be useful to detect subclinical increase of CS activity, which expands the spectrum of patients that would benefit from a better CS activity assessment., This study was funded with a research grant from Alexion and a grant from the Spanish Society of Nephrology. JL-R is recipient of a Rio Hortega grant from Instituto de Salud Carlos III (CM23/00213). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292), Fundació la Marató de TV3 (202017-10, 202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Prediabetes and CKD: Does a causal relationship exist, Prediabetes y ERC: ¿existe una relación causal?

  • Rico-Fontalvo, Jorge
  • daza arnedo, rodrigo andres
  • Navarro-Blackaller, Guillermo
  • Medina-Gonzalez, Ramon
  • Rodriguez Yanez, Tomas
  • Soler, María José
Prediabetes; Chronic kidney disease; Albuminuria, Prediabetes; Enfermedad renal crónica; Albuminuria, Prediabetis; Malaltia renal crònica; Albuminuria, The relationship between diabetes and the development of kidney complications is well known, but the understanding of prediabetes and insulin resistance with impaired kidney function has been scarcely assessed. Various factors could explain this phenomenon, from the lack of standardization in the definitions of prediabetes, to the erratic and inconsistent evidence in large-scale epidemiological and cohort studies. It seems that the pathophysiological pathway of prediabetes could be related to inflammation and neurohormonal hyperactivation, factors present even before the onset of diabetes, which might be the main drivers of glomerular hyperfiltration, albuminuria, and impaired glomerular filtration rate. It is possible that existing treatments for the management of diabetes, as metformin or SGLT2 inhibitors may also be useful in patients with prediabetes with evidence of functional and structural kidney damage. The purpose of this review is to summarize the evidence regarding the relationship between prediabetes (preDM) and the development of CKD., La relación entre diabetes y el desarrollo de complicaciones renales es bien conocida; sin embargo la asociación entre prediabetes y la resistencia a la insulina con el daño en la función renal apenas ha sido evaluada. Varios factores podrían explicar este fenómeno, desde la falta de estandarización en las definiciones de prediabetes, hasta la errática e inconsistente evidencia en estudios epidemiológicos y de cohortes a gran escala. Parece que las vías fisiopatológicas en la prediabetes podrían estar relacionadas con inflamación y la hiperactivación del sistema neuro-hormonal, factores presentes incluso antes de la aparición de la diabetes, que podrían ser los principales impulsores de la hiperfiltración glomerular, albuminuria y alteración de la tasa de filtración glomerular. Es posible que los tratamientos existentes para el control de la diabetes, como metformina o los inhibidores SGLT2 también pueden ser útiles en pacientes con prediabetes con evidencia de daño renal funcional o estructural. El propósito de esta revisión es resumir la evidencia sobre la relación entre la prediabetes (preDM) y el desarrollo de la ERC., M.J.S. is funded by ISCIIII-FEDER and ISCIII, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Trypsin Partially Cleaves Apolipoprotein A-I (ApoA-I) Precursor into Mature ApoA-I Hindering the Quantification of Naturally Occurring ApoA-I Proteoforms by Liquid Chromatography in Multiple Reaction Monitoring Mode Mass Spectrometry (LC-MRM-MS)

  • Núñez-Seral, Norberto
  • Martínez Díaz, Irene
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Villena-Ortiz, Yolanda
  • Soler, María José
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
Apolipoproteína; Cromatografía líquida; Espectrometría de masas, Apolipoprotein; Liquid chromatography; Mass spectrometry, Apolipoproteïna; Cromatografia líquida; Espectrometria de masses, Apolipoprotein A-I (ApoA-I), one of the most abundant proteins in plasma and the major protein component of high-density lipoprotein (HDL), is naturally found in several proteoforms; two of them are ProApoA-I and mature ApoA-I. These two proteoforms of ApoA-I coexist in biological samples and differ only in their N-terminal end. Virtually, the only way to differentiate them is by detecting the proteoform-specific N-terminal proteolytic peptides (RHFWQQDEPPQSPWDR and DEPPQSPWDR, respectively) using liquid chromatography in multiple reaction monitoring mode mass spectrometry (LC-MRM-MS). We have developed a bottom-up LC-MRM-MS method to simultaneously detect proApoA-I and mature ApoA-I. To test the specificity of the method, we digested with trypsin purified mature ApoA-I and recombinant proApoA-I. As expected, only the N-term peptide corresponding to the mature ApoA-I proteoform (DEPPQSPWDR) was detected when digesting mature ApoA-I. However, the digestion of the proApoA-I produced not only the N-terminal peptide corresponding to proApoA-I (RHFWQQDEPPQSPWDR) but also the N-terminal tryptic peptide corresponding to mature ApoA-I (DEPPQSPWDR). This effect was produced by standard and high-specificity trypsin as well as by the Arg-C enzyme in a self-limited manner (approximately 10% of the total). The synthetic proApo-I peptide is not cleaved by trypsin, suggesting that the here reported effect is dependent on protein conformation. The effect is not negligible, as it can be detected by LC-MRM-MS, and correction calculations should be applied to accurately quantify proApoA-I and mature ApoA-I in biological samples where these two proteoforms may coexist., C.L.C. performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. We thank Mandy Rettel from the PCF of EMBL for technical assistance. The study was funded with a grant from Fundació la Marató de TV3 (ref 202017-10). The authors are recipients of research grants from Instituto de Salud Carlos III (AC22/00029, PI21/01292) and Fundació la Marató de TV3 (202037-31 and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, drug delivery, and therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Paraneoplastic Syndrome After Kidney Transplantation: Frequency, Risk Factors, Differences to Paraneoplastic Occurrence of Glomerulonephritis in the Native Kidney, and Implications on Long-Term Kidney Graft Function

  • Zakrocka, Izabela
  • Nair, Gayatri
  • Jhaveri, Kenar D
  • Kronbichler, Andreas
  • Soler, María José
Glomerulonephritis; Paraneoplastic syndrome; Transplantation, Glomerulonefritis; Síndrome paraneoplàsica; Ttrasplantament, Glomerulonefritis; Síndrome paraneoplásico; Trasplante, Posttransplant malignancies are an important complication of solid organ transplantation. Kidney transplant recipients are at particularly high risk of cancer development. The most relevant risk factors of carcinogenesis are the use of immunosuppressive agents and oncogenic viral infections. Additionally, immune dysregulation caused by these factors may predispose to various types of organ damage. Paraneoplastic glomerular diseases are one of the most interesting and understudied cancer manifestations. The appropriate diagnosis of paraneoplastic glomerular damage can be challenging in kidney transplant recipients, due to factors inherent to concomitant medication and common comorbidities. Recent advances in the field of molecular and clinical nephrology led to a significant improvement in our understanding of glomerular diseases and their more targeted treatment. On the other hand, introduction of novel anticancer drugs tremendously increased patients’ survival, at the cost of kidney-related side effects. Our review aims to provide insights into diagnosis and treatment of paraneoplastic glomerular diseases, with a special attention to kidney transplant recipients., The authors declare that financial support was received for the research, authorship, and/or publication of this article. MS is supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, PI17/00257, PI20/00744, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), BECA SENFRO 2021, RD21/0005/0016 (RICORS 2040), and ERA-PerMed-JTC 2022 (ONAKI-ICI AC22/00029).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies

  • León-Román, Juan
  • Bolufer Cardona, Monica
  • Sánchez-Salinas, Mario
  • Alonso-Martínez, Carla
  • Bestard, Oriol
  • Bermejo García, Sheila
  • Cecilia del Carmen, Carpio Segura
  • Garcia-Carro, Clara
  • Barba, Pere
  • Soler, María José
  • IACOBONI, GLORIA
CAR-T therapy; Acute kidney injury; Onconephrology, Terapia CAR-T; Lesión renal aguda; Onconefrología, Teràpia CAR-T; Lesió renal aguda; Onconefrologia, Background Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy. Methods Medical records of 115 adult patients with R/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion. Results A total of 24/115 (21%) patients developed AKI related to CAR T-cell therapy; 6/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade ≥3 and CRS grade ≥2 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade ≥2 associated to ICANS grade ≥2, and 1 for CRS grade ≥3). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure. Conclusion Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients., P.B. received research funding from the Carlos III Health Institute (PI21/0199,INT23/00072), Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018-2020 grant from the Generalitat de Catalunya (BDNS357800). This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, grant number PI21/01292, ERA PerMed JTC2022 grant number AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units

  • León-Román, Juan
  • Azancot Rivero, M Antonieta
  • Marouço, Catarina
  • Patricio-Liébana, Marc
  • Ramos Terrades, Natalia
  • Núñez Delgado, Sara
  • Zamora Carrillo, Jorge Ivan
  • TOAPANTA, NÉSTOR
  • Méndez Fernández, Ana Belén
  • Soler, María José
Cardiorenal syndrome; Chronic kidney disease; Heart failure, Síndrome cardiorrenal; Enfermedad renal crónica; Insuficiencia cardíaca, Síndrome cardiorenal; Malaltia renal crònica; Insuficiència cardíaca, Introduction: Approximately 70% of patients with heart failure (HF) also have kidney disease. Mortality is increased both by cardiorenal syndrome (CRS) and by the exacerbation of other comorbidities. The purpose of this study is to evaluate the clinical performance of patients with CRS who are followed up by the Cardiorenal Unit (CRU). Methods: We conducted a retrospective observational study of patients referred to the CRU from April 1, 2022, to April 30, 2023. Demographics, laboratory and ultrasonographic tests, and outcomes were evaluated. Results: Fifty-four patients were seen in the CRU. A total of 45 (83%) and 16 (30%) patients completed follow-up in the CRU at 6 and 12 months, respectively. The mean age was 70 years ± 1.6, and 65% were men. Almost 50% of patients had ischemic heart disease-related HF. The mean cardiac ejection fraction (EF) was 40% ± 1.6, and 61% of patients had HF with reduced EF (HFrEF). NYHA functional classes II and III were the most frequent (60% and 35%, respectively). At 6 months after follow-up, treatment was optimized with sacubitril-valsartan in 33% vs. 49% (p = 0.02) and SGLT2 inhibitors in 48% vs. 72% (p = 0.008), without significant deterioration in renal function (creatinine: p = 0.61; eGFR: p = 0.19). There was also a reduction of more than 50% in the number of hospital admissions (p = 0.002). A total of 22% required peritoneal dialysis, and 20% required hemodialysis. Ten (19%) patients died, five of them due to cardiovascular (CV) events. Conclusions: The CRU is vital for the management of complex patients as it ensures the implementation of medications that reduce CV mortality and decrease the number of hospital admissions in HF., This research was funded by ISCIIII-FEDER and ISCIII RETICS REDinREN, Grant No. PI21/01292, PI24/01510, ERA PerMed JTC2022 Grant No. AC22/00029, Río Hortega CM23/00213, Marató TV3 421/C/2020, Marató TV3 215/C/2021, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas, PI23/01209 Proyectos de I+D+I en Salud AES2023.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).